NCT00554216View on ClinicalTrials.gov

Study of VI-0521 Compared to Placebo in Treatment of Obesity in Adults

PHASE3CompletedINTERVENTIONAL
Enrollment

1,267

Participants

Timeline

Start Date

November 30, 2007

Primary Completion Date

May 31, 2009

Study Completion Date

May 31, 2009

Conditions
Obesity
Interventions
DRUG

VI-0521

3.75 mg phentermine/23 mg topiramate

DRUG

VI-0521

15 mg phentermine/92 mg topiramate

DRUG

Placebo matched phentermine/topiramate

Placebo matched phentermine/topiramate

Trial Locations (5)

27710

Research Site, Durham

43623

Research Site, Toledo

78731

Research Site, Austin

92130

Research Site, San Diego

06877

Research, Ridgefield

Sponsors

Collaborators (1)

Medpace, Inc.
All Listed Sponsors
collaborator

Medpace, Inc.

INDUSTRY

lead

VIVUS LLC

INDUSTRY